drugset
drugset / Trial / NCT05400967

Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI

NCT05400967 ↗

Phase 0 Recruiting 10 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelTreatment

Summary

FAP is a fibroblast activation protein and overexpressed in many tumor tissues. This study is intended to conduct preliminary clinical transformation and internal irradiation dosimetry research on 177Lu-EB-FAPI--a new 177Lu therapeutic drug modified by Evans Blue (EB) for the first time in the world.

Timeline

Start
2022-01-01
Primary completion
2025-01-01
Completion
2025-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 177Lu-EB-FAPI Other / unclassified 2220 mbq Intravenous
Subject FAPI GA-68 Diagnostic / imaging agent — —

Indications

No indication recorded.